Abstract 1458P
Background
Pucotenlimab is a novel anti-PD-1 IgG4 monoclonal antibody. Several clinical trials conducted in China have demonstrated its efficacy and safety in various solid tumors including gastric cancer and breast cancer. Here we report a phase II study result of pucotenlimab for nsq-NSCLC without EGFR/ALK mutations.
Methods
In this open-label phase II study, patients naive to systemic treatment were enrolled with histologically diagnosed stage IIIB or IV nsq-NSCLC. Patients were received intravenous Pucotenlimab 200mg Q3w for up to 35 cycles, combined with platinum + pemetrexed Q3W for 4 cycles and followed by maintenance pemetrexed Q3W (all intravenous). The primary endpoint was overall response rate (ORR) and safety, and the secondary endpoints were progression-free survival (PFS), duration of response (DOR) and overall survival (OS).
Results
From September 25th, 2020 to April 15th, 2021, a total of 43 patients were enrolled and followed up with a median of 13.1 months by the cut-off date (August 3th, 2022). 22 patients achieved partial response and 20 remained stable disease, respectively, contributing an ORR of 48.8% (95%CI: 38.9%, 59.2%) and a DCR of 95.3% (95%CI: 88.7%, 98.4%). The median PFS, DOR were 11.1 months (95%CI: 6.8, 14.4) and 13.9 (95%CI: 6.6, NE) months, respectively. The median OS was not reached. The common treatment-related adverse events (TRAEs) of any grade included anemia (79.1%), neutrophil count decreased (72.1%), white blood cell count decreased (67.4%) and platelet count decrease (53.5%). Neutrophil count decreased (32.6%) was the most reported grade 3/4 TRAE.
Conclusions
Pucotenlimab combined with pemetrexed plus platinum demonstrated promising efficacy and safety for the 1st line nsq-NSCLC patients without EGFR/ALK mutations.
Clinical trial identification
NCT04750083.
Editorial acknowledgement
Legal entity responsible for the study
Taizhou Hanzhong Biomedical Co. Ltd.
Funding
Taizhou Hanzhong Biomedical Co. Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Presenter: Sara Hijazo-Pechero
Session: Poster session 20
1420P - Real-life management of octogenarians with NSCLC in a French nationwide cohort
Presenter: Romain Corre
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20